NASDAQ · SLGC
SomaLogic, Inc.
$2.10-$0.10 (-4.55%)
SomaLogic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.59% below the high.
Loading market information…
NYSE · MPLN · USD
Stock price, earnings
Quote as of Feb 27, 2025, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
MultiPlan Corporation’s quoted price sits in the upper half of its reported 52-week range, 39.85% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow MultiPlan Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
MultiPlan Corporation, through its various subsidiaries, supplies advanced data analytics and technology-driven solutions to the United States healthcare sector. These services are primarily aimed at optimizing cost management, streamlining payment processes, and ensuring the accuracy of revenue. The company leverages sophisticated algorithms and data-informed insights to deliver analytics-based services that effectively reduce medical expenses. This is achieved by detecting inflated charges on claims and either negotiating or recommending fair reimbursement amounts. Furthermore, MultiPlan offers network-focused services, which involve securing discounted rates with healthcare providers and managing the outsourced development and administration of provider networks. Its payment and revenue integrity solutions are vital for pinpointing and eliminating improper or unnecessary charges paid during the claims procedure. These services also extend to identifying and aiding in the recovery and retention of underpaid premium funds. The firm's data and decision science division provides a complete suite of solutions that employ modern data science techniques. These produce descriptive, predictive, and prescriptive analytics designed to refine benefit plan designs, facilitate strategic decision-making, enhance clinical outcomes, and lower the overall cost of care. MultiPlan also manages business-to-business healthcare payments and offers other related services. A diverse clientele benefits from MultiPlan's offerings, including major national and regional insurance carriers, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, Third-Party Administrators (TPAs), self-insured health plans, property and casualty insurers, bill review entities, and other organizations participating in the claim adjudication process. MultiPlan Corporation was founded in 1980 and is headquartered in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:08 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2024 |
|---|
| May 8, 2024 |
| -$33.20-1,453.71% vs estimate |
| $234.51M-3.94% vs estimate |
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.10-$0.10 (-4.55%)
SomaLogic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.59% below the high.
$3.65$0.00 (0.0%)
Revance Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.72% below the high.
$16.70+$0.05 (+0.3%)
Orchard Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
$7.16+$0.01 (+0.14%)
G1 Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.42% below the high.
$8.05$0.00 (0.0%)
Vigil Neuroscience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.62% below the high.
$4.26$0.00 (0.0%)
Checkpoint Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.33% below the high.
$10.50+$0.09 (+0.86%)
Tabula Rasa HealthCare, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.95+$0.00 (+0.11%)
Global Cord Blood Corporation’s quoted price sits in the lower half of its reported 52-week range, 45.66% below the high.
